{
"id":"mk19_b_en_s4",
"subspecialtyId":"en",
"title":"Disorders of the Thyroid Gland",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s4",
"title":{
"__html":"Disorders of the Thyroid Gland"
},
"titleNode":{
"type":"section-title",
"hlId":"2b0b7c",
"children":[
"Disorders of the Thyroid Gland"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s4_1",
"title":{
"__html":"Thyroid Anatomy and Physiology"
},
"titleNode":{
"type":"section-title",
"hlId":"f841b9",
"children":[
"Thyroid Anatomy and Physiology"
]
},
"children":[
{
"type":"p",
"hlId":"da7779",
"children":[
"The thyroid consists of right and left lobes connected by a median isthmus that is anterior to the second to fourth tracheal rings. The parathyroids are behind the right and left thyroid lobes, two superiorly and two inferiorly. The recurrent laryngeal nerves course behind the thyroid. Because of the thyroid's proximity to the trachea, esophagus, and recurrent laryngeal nerves, thyroid pathology may cause compressive symptoms including dyspnea, cough, dysphagia, and hoarseness."
]
},
{
"type":"p",
"hlId":"aa08bb",
"children":[
"The thyroid contains parafollicular cells (also called C cells) and follicular cells. Parafollicular cells produce calcitonin, which inhibits bone resorption, playing a minor role in bone physiology. Follicular cells produce thyroid hormones thyroxine (T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
") and triiodothyronine (T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
")",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"."
]
},
" The hypothalamic-pituitary-thyroid axis regulates thyroid hormone synthesis and secretion. Hypothalamic thyrotropin-releasing hormone triggers the pulsatile release of thyroid-stimulating hormone (TSH) from the anterior pituitary. TSH stimulates thyroid cell growth, iodide uptake, and thyroid hormone synthesis and secretion. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" exert negative feedback on the hypothalamus and pituitary, which further moderates hormone synthesis."
]
},
{
"type":"p",
"hlId":"941e81",
"children":[
"The thyroid is the exclusive source of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", whereas approximately 80% of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" is from peripheral T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" deiodination, primarily in the liver and kidney. Most of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" (99.96%) and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" (99.6%) are bound to serum proteins, whereas approximately 70% of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" are bound to T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
"-binding globulin (TBG). Albumin, transthyretin, and lipoproteins carry a smaller proportion. Only free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" are biologically available. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" serves as a prohormone, and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" binds with high affinity to cellular nuclear receptors affecting gene transcription in target tissues. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" has positive cardiac inotropic and chronotropic effects, enhances myocardial adrenergic sensitivity, increases myocardial diastolic relaxation, augments intravascular volume, and lowers peripheral vascular resistance. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" also increases gastrointestinal motility, bone turnover, heat generation, and energy expenditure."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_2",
"title":{
"__html":"Thyroid Examination"
},
"titleNode":{
"type":"section-title",
"hlId":"9cf6c4",
"children":[
"Thyroid Examination"
]
},
"children":[
{
"type":"p",
"hlId":"037f61",
"children":[
"The thyroid is located in the neck between the sternal notch and thyroid cartilage. It attaches to the trachea posteriorly and elevates with swallowing and neck extension. Examination involves both inspection and palpation while the patient swallows liquid with the neck slightly extended (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v05",
"wrapId":"1",
"children":[
"Video 5"
]
}
]
},
"). With the examiner behind the patient, circumferential hand positioning allows focusing on palpation. With the examiner facing the patient, inspection of the thyroid during palpation is possible. The anterior approach is preferred for larger diameter necks. With either approach, it is important for the examiner's fingers to curve along the tracheal surface posteriorly (i.e., the examiner's right hand evaluates the patient's left lobe and vice versa)."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_v05"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_3",
"title":{
"__html":"Structural Disorders of the Thyroid Gland"
},
"titleNode":{
"type":"section-title",
"hlId":"8d2036",
"children":[
"Structural Disorders of the Thyroid Gland"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s4_3_1",
"title":{
"__html":"Thyroid Nodules"
},
"titleNode":{
"type":"section-title",
"hlId":"6c1448",
"children":[
"Thyroid Nodules"
]
},
"children":[
{
"type":"p",
"hlId":"effbf0",
"children":[
"Palpable nodules are found in 5% of women and 1% of men (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v06",
"wrapId":"2",
"children":[
"Video 6"
]
}
]
},
"). Of the U.S. population, 40% have nodules identified on ultrasound, with an increasing incidence with age. Causes of thyroid nodules range from benign cysts and inflammatory nodules to malignancies, including primary thyroid, lymphoma, or metastases. Nonthyroidal lesions, such as parathyroid adenomas, can also present as thyroid nodules. Primary thyroid neoplasms include follicular adenomas and thyroid cancer. Approximately 5% of thyroid nodules contain malignancy. Approximately 35% of incidental thyroid nodules identified on PET scan may be malignant. Family history suggestive of multiple endocrine neoplasia (MEN) 2A and 2B (i.e., pheochromocytoma, medullary thyroid cancer, primary hyperparathyroidism) increases the risk for medullary thyroid cancer."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_v06"
]
},
{
"type":"p",
"hlId":"02b5bb",
"children":[
"The initial laboratory evaluation of a thyroid nodule begins with measuring TSH ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f09",
"wrapId":"3",
"children":[
"Figure 9"
]
}
]
},
")"
]
},
". TSH suppression is found with autonomously functioning or “hot” nodules, accounting for 5% to 10% of palpable thyroid nodules. Patients with thyroid nodules and a suppressed TSH are evaluated with thyroid scintigraphy. A radioactive isotope, preferably iodine 123 (",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"123"
]
},
"I), is administered; the percentage taken up by the thyroid is calculated (radioactive iodine uptake [RAIU]), and an image is obtained (thyroid scan). Hot nodules concentrate radioactive iodine (",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I) to a greater extent than normal thyroid tissue. Autonomous “hot” nodules have a very low risk of malignancy and do not require fine-needle aspiration biopsy (FNAB)."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_f09"
]
},
{
"type":"p",
"hlId":"776e8c",
"children":[
"If TSH is normal or elevated, thyroid ultrasonography is required to confirm and characterize the nodule(s). Symptoms and the ultrasound appearance guide the management of nonfunctioning nodules. The 2015 American Thyroid Association guidelines classify thyroid nodules into five sonographic patterns based on echogenicity; whether they are solid, cystic, or both; and features of malignancy. These characteristics and nodule size determine the need for biopsy. FNAB is not recommended for subcentimeter nodules unless associated with symptoms, pathologic lymphadenopathy, extrathyroidal extension, history of childhood radiation exposure, or familial thyroid cancer syndrome ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t33",
"wrapId":"4",
"children":[
"Table 33"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_en_t33"
]
},
{
"type":"p",
"hlId":"34dc1b",
"children":[
"Thyroid nodule FNAB should be performed under ultrasound guidance when possible because of improved accuracy. Thyroid cytopathology is interpreted and classified according to the Bethesda classification system and summarized in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t34",
"wrapId":"5",
"children":[
"Table 34"
]
}
]
},
". Approximately 60% to 70% of biopsied nodules have benign cytology, 20% are indeterminate, and 5% to 10% have evidence of malignancy. Thyroid FNAB cytology can be nondiagnostic in 5% to 10% of specimens. Endocrine referral is recommended for Bethesda III-V classified nodules."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_en_t34"
]
},
{
"type":"p",
"hlId":"d7f650",
"children":[
"Clinical monitoring is indicated for all thyroid nodules and should include TSH measurement, because structural abnormalities in the thyroid lead to increased risk for thyroid dysfunction (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s4_5",
"children":[
"Disorders of Thyroid Function"
]
},
"). The American Thyroid Association sonographic pattern and clinical context guide the timing for follow-up after the initial ultrasound for benign nodules and nodules not evaluated with FNAB. Repeat ultrasonography should be performed in 6 to 12 months for all high-suspicion nodules, 12 to 24 months for intermediate- and low-suspicion nodules, and 24 months or longer for very low-suspicion nodules. Repeat FNAB is indicated for all high-suspicion nodules, nodules with concerning new sonographic findings, and intermediate- or low-suspicion nodules that increase 20% in at least two dimensions or by 50% in nodule volume. Repeat FNAB is not recommended for nodules with two benign biopsy results."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3f65ae",
"children":[
"The initial evaluation of a thyroid nodule begins with measuring serum thyroid-stimulating hormone."
]
},
{
"type":"keypoint",
"hlId":"481959",
"children":[
"Patients with a suppressed thyroid-stimulating hormone (TSH) level are evaluated with thyroid scintigraphy; those with normal or elevated TSH are evaluated with ultrasonography."
]
},
{
"type":"keypoint",
"hlId":"127f3e",
"children":[
"Thyroid nodule characteristics and size determine the need for fine-needle aspiration biopsy."
]
},
{
"type":"keypoint",
"hlId":"734700",
"hvc":true,
"children":[
"Fine-needle aspiration biopsy is not recommended for subcentimeter thyroid nodules unless associated with symptoms, pathologic lymphadenopathy, extrathyroidal extension, history of childhood radiation exposure, or familial thyroid cancer syndrome."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_3_2",
"title":{
"__html":"Goiters"
},
"titleNode":{
"type":"section-title",
"hlId":"1450a0",
"children":[
"Goiters"
]
},
"children":[
{
"type":"p",
"hlId":"73fcbb",
"children":[
"Goiter is an enlarged thyroid ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f10",
"wrapId":"6",
"children":[
"Figure 10"
]
}
]
},
")"
]
},
". Goiters can be associated with normal thyroid function, hypothyroidism, or hyperthyroidism. The most common cause worldwide is iodine deficiency. Patients presenting with goiter should be questioned about iodine intake, rate of change in size, and thyroid cancer risk factors (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s4_3_5",
"children":[
"Thyroid Cancer"
]
},
"). Clinical history should focus on symptoms of thyroid hormone excess or deficiency and compression. Compressive symptoms include dyspnea, cough, dysphagia, and voice changes, which are evident in 10% to 20% of patients with goiter. Examination should note the thyroid size, symmetry, and consistency as well as the presence of nodules or adenopathy and tracheal deviation. Possible venous obstruction is assessed with the patient's arms raised above the head. The findings of jugular venous distension, facial plethora, and flushing indicate thoracic outlet obstruction with reduced venous return ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f11",
"wrapId":"6",
"children":[
"Figure 11"
]
}
]
},
")"
]
},
". The first laboratory step to assess goiter is to measure TSH. If low, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" should be measured and thyroid scintigraphy performed. If normal or elevated, thyroid ultrasonography is indicated in patients at risk for thyroid cancer or if palpable thyroid nodules, gland asymmetry, large goiter, rapid growth, or compressive symptoms are present. Patients with signs or symptoms of compression require additional testing (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s4_3_3",
"children":[
"Multinodular Goiter"
]
},
"), and surgery may be needed for symptomatic management. Treatment of hypothyroid and hyperthyroid conditions in the setting of goiter is discussed later throughout text."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_en_f10",
"mk19_b_en_f11"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1cfdb8",
"children":[
"Patients with goiter should be questioned about iodine intake, rate of change in size, and thyroid cancer risk factors; assessed for signs and symptoms of compression; and evaluated for clinical manifestations of thyroid hormone excess or deficiency."
]
},
{
"type":"keypoint",
"hlId":"3b039c",
"children":[
"Serum thyroid-stimulating hormone should be assessed in patients with goiter; if low, free thyroxine and total triiodothyronine should be measured and thyroid scintigraphy performed; if thyroid-stimulating hormone is normal or elevated, thyroid-neck ultrasonography is indicated in patients at risk for thyroid cancer or if palpable thyroid nodules, gland asymmetry, large goiter, rapid growth, or compressive symptoms are present."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_3_3",
"title":{
"__html":"Multinodular Goiter"
},
"titleNode":{
"type":"section-title",
"hlId":"038df3",
"children":[
"Multinodular Goiter"
]
},
"children":[
{
"type":"p",
"hlId":"28a706",
"children":[
"Multinodular goiter (MNG) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f12",
"wrapId":"7",
"children":[
"Figure 12"
]
}
]
},
")"
]
},
" is the most common cause of thyroid enlargement in older adults in the United States. Evaluation includes measurement of TSH. For cases in which TSH is not suppressed, thyroid ultrasonography should be performed and discrete nodules evaluated (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s4_3_1",
"children":[
"Thyroid Nodules"
]
},
"). The frequency of malignancy in patients with MNG is similar to those with solitary thyroid nodules. Signs and symptoms of compression or suspected substernal extension require additional testing. CT or MRI of the neck and chest (when substernal goiter is suspected) can define anatomic relationships and assess for tracheal narrowing. Administration of iodinated contrast should be avoided if possible because of the potential to precipitate iodine-induced hyperthyroidism (Jod-Basedow phenomenon). A flow-volume loop study is indicated in patients with symptoms of airway compression or when the tracheal lumen measures less than 1 cm in diameter on CT or MRI (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s1_1_4",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
"). Endoscopy or a swallowing study can assess for extrinsic compression of the esophagus in patients with cervical dysphagia. Consultation with an otolaryngologist is indicated to confirm clinically suspected vocal cord paralysis. Surgery is indicated for significant compression or suspected malignancy."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_en_f12"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_3_4",
"title":{
"__html":"Diffuse Goiter"
},
"titleNode":{
"type":"section-title",
"hlId":"41aa12",
"children":[
"Diffuse Goiter"
]
},
"children":[
{
"type":"p",
"hlId":"742650",
"children":[
"The most common cause of diffuse goiter in the United States is autoimmune thyroid disease associated with thyroid dysfunction (Hashimoto thyroiditis and Graves disease). Rare causes of diffuse goiter are infiltrative disorders, such as Riedel (IgG4-related) thyroiditis. Diffuse goiter may also occur in euthyroid patients in absence of predisposing inflammatory or neoplastic processes. Genetic predisposition, iodine insufficiency, and cigarette smoking are contributing factors. Thyroid ultrasonography is indicated in euthyroid patients with diffuse goiter. Ultrasonography is also recommended for patients with Graves disease or Hashimoto thyroiditis when examination shows thyroid asymmetry or nodules. Additional testing is indicated if compressive signs or symptoms are present. Thyroid surgery is considered in the setting of significant compression."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_3_5",
"title":{
"__html":"Thyroid Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"f716b2",
"children":[
"Thyroid Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"bd28b5",
"children":[
"Thyroid cancer is diagnosed in 13.9 per 100,000 people per year in the United States. Thyroid cancer incidence has increased during the past four decades and now is the fifth most common cancer in women. Much of this change is attributable to a rise in the diagnosis of small noninvasive cancers, detected incidentally on imaging for other reasons (carotid Doppler studies, neck/chest CT, PET scan). Mortality rates have remained stable with an overall 5-year survival rate of 98.1%. The stable mortality rate in the setting of increased incidence suggests the possible overdiagnosis of clinically insignificant tumors. Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma comprise most of the thyroid cancer diagnoses in the United States. PTC commonly spreads to cervical lymph nodes but is associated with a low risk of distant metastases. In follicular thyroid carcinoma, lymph node spread is rare, but metastases to lung, bone, and other sites are possible. The types and frequency of thyroid cancer are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f13",
"wrapId":"8",
"children":[
"Figure 13"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_en_f13"
]
},
{
"type":"p",
"hlId":"fc5820",
"children":[
"Risk factors for thyroid cancer include a history of ionizing radiation exposure and a personal or family history of thyroid cancer. PTC is increased in those exposed to ionizing radiation, with the highest risk for patients with childhood exposures, such as treatment of childhood cancer and with nuclear accidents. Additional risk factors for thyroid cancer include a first-degree relative with a history of thyroid cancer or a familial thyroid cancer syndrome. Rapid nodule growth, a hard fixed nodule, dysphagia, hoarseness, and cervical lymphadenopathy suggest malignancy. The diagnosis is confirmed by FNAB."
]
},
{
"type":"p",
"hlId":"f82ae0",
"children":[
"Surgery is the mainstay of thyroid cancer treatment. Either total thyroidectomy or hemithyroidectomy is acceptable for unilateral differentiated thyroid cancers with nodules 1 to 4 cm if locoregional spread is not suspected. Total thyroidectomy is otherwise indicated. Risks of thyroid surgery include hypocalcemia from parathyroid injury or removal and difficulty breathing or voice changes from recurrent laryngeal nerve injury. Referral to a high-volume thyroid surgeon (>100 cases per year) lowers the risk of postoperative complications."
]
},
{
"type":"p",
"hlId":"e4f3fd",
"children":[
"No additional treatment is required for low-risk PTC, defined as confined to the thyroid, completely resected, not metastasized, and without aggressive pathologic features (lymphovascular invasion or tall cell variant). The risk of disease-related death is less than 1%, and the risk of recurrence is 1% to 2% for low-risk unifocal papillary microcarcinomas. Patients receiving either lobectomy or thyroidectomy have similarly excellent outcomes."
]
},
{
"type":"p",
"hlId":"51f51e",
"children":[
"Postoperative ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I should be considered for thyroid remnant ablation and adjuvant therapy for differentiated thyroid cancer with an intermediate to high risk of recurrence, such as with extrathyroidal extension, lymph node involvement, vascular invasion, poorly differentiated or more aggressive histology, or metastatic disease. A high TSH (>30 μU/mL [30 mU/L]) achieved by either levothyroxine withdrawal or recombinant TSH administration combined with a low-iodine diet for 10 to 14 days increases ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I uptake by both normal thyroid and differentiated thyroid cancer cells. Following ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy, whole-body scanning can identify areas of ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I uptake corresponding to metastatic disease. ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy also treats cancer recurrences not amenable to resection."
]
},
{
"type":"p",
"hlId":"187370",
"children":[
"After initial cancer treatment with total thyroidectomy and ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I ablation, serum thyroglobulin (Tg), which is produced only by the thyroid, and Tg antibody (TgAb) titers are monitored. Persistent Tg levels suggest recurrent or persistent disease. When TgAb is present, Tg levels are uninterpretable because TgAb can falsely lower Tg. In this case, the TgAb serves as a surrogate marker. A decreasing TgAb titer over time correlates with a favorable prognosis, whereas an increasing titer is suspicious for persistent or recurrent disease. The presence of TgAb does not affect the measurement of Tg by mass spectrometry."
]
},
{
"type":"p",
"hlId":"e9206d",
"children":[
"Thyroid ultrasonography is repeated in routine thyroid cancer surveillance, 6 to 12 months after the initial cancer treatment. In patients at high risk of recurrent disease, diagnostic ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"123"
]
},
"I or ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I whole-body scanning with TSH-stimulated Tg measurement can be performed. If residual or recurrent thyroid cancer is suspected, such as when serum Tg is persistently elevated or increasing over time, but not identified by neck ultrasonography or ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I whole-body scanning, CT, MRI, bone scan, or fluorodeoxyglucose PET/CT scan can be useful."
]
},
{
"type":"p",
"hlId":"6a742b",
"children":[
"Treatment of intermediate to high-risk differentiated thyroid cancer also includes TSH suppression with daily levothyroxine. Thyroid follicular cells are TSH responsive, as are most well-differentiated thyroid cancers. Levothyroxine is administered lifelong to suppress the TSH with the target TSH appropriate for the risk of recurrence. Low-risk thyroid cancer has a TSH target between the lower limit of the reference range to 2 μU/mL (2 mU/L). High-risk thyroid cancer has a TSH target of less than 0.1 μU/mL (0.1 mU/L). Metastatic thyroid cancer is managed with active surveillance, additional surgery, or ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy, as well as external beam radiation therapy and/or chemotherapy (tyrosine kinase inhibitors)."
]
},
{
"type":"p",
"hlId":"2db643",
"children":[
"Anaplastic thyroid cancer is a rare, aggressive thyroid malignancy occurring de novo or in patients with preexisting differentiated thyroid cancer. Anaplastic thyroid cancer presents with a rapidly enlarging neck mass and may be unresectable at the time of diagnosis. The median survival for these patients is 5 months. Treatment is palliative in most cases and includes surgery, external beam radiation therapy, and chemotherapy."
]
},
{
"type":"p",
"hlId":"a4358e",
"children":[
"Medullary thyroid cancer arises from parafollicular cells. Germline ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"RET"
]
},
" oncogene mutations occur with familial medullary thyroid cancer and MEN 2A and 2B. MEN should be ruled out with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"RET"
]
},
" genetic testing before surgery; if present, the patient should be screened for pheochromocytoma. If this rare tumor is present, it should be treated first. Medullary thyroid cancer is treated with total thyroidectomy and central neck lymph node dissection. Levothyroxine is indicated to treat postoperative hypothyroidism in patients with medullary thyroid cancer, with a goal TSH level within the reference range. Serum calcitonin, serum carcinoembryonic antigen levels, and neck ultrasonography are part of routine cancer surveillance."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2d7c73",
"children":[
"Thyroid cancer incidence has increased during the past four decades, which is attributed to an increase in the diagnosis of small noninvasive cancers."
]
},
{
"type":"keypoint",
"hlId":"1116ba",
"children":[
"Surgery is the mainstay of thyroid cancer treatment; either hemithyroidectomy or total thyroidectomy is acceptable for unilateral differentiated thyroid cancers with 1- to 4-cm nodules if locoregional spread is not suspected; total thyroidectomy is preferred in all other cases."
]
},
{
"type":"keypoint",
"hlId":"5c7e4a",
"children":[
"In addition to surgery, patients with differentiated thyroid cancer and an intermediate to high risk of recurrence are treated with radioactive iodine therapy and individualized thyroid-stimulating hormone suppression with levothyroxine."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_4",
"title":{
"__html":"Evaluation of Thyroid Function"
},
"titleNode":{
"type":"section-title",
"hlId":"f8566f",
"children":[
"Evaluation of Thyroid Function"
]
},
"children":[
{
"type":"p",
"hlId":"be74c6",
"children":[
"Serum TSH is the most sensitive thyroid function test in patients with normal pituitary function. If TSH is suppressed, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" should be assessed to detect overt or subclinical hyperthyroidism. If TSH is elevated, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" should be assessed to detect overt or subclinical hypothyroidism. Measuring TSH alone as an initial test is sufficient except in suspected central hypothyroidism, for which free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" measurement is preferred (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s2_4_3",
"children":[
"Disorders of the Pituitary Gland"
]
},
"). Thyroid function should not be assessed in hospitalized patients unless clinical suspicion of thyroid dysfunction is strong (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s4_7",
"children":[
"Nonthyroidal Illness Syndrome"
]
},
")."
]
},
{
"type":"p",
"hlId":"edc2d7",
"children":[
"Total and free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" concentrations can be assessed with various assays that are accurate in most patients with overt thyroid dysfunction; commercially available free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" assays are less reliable. Total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" levels vary based on binding protein levels and may not reflect actual thyroid function. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
"-binding protein perturbations occur with physiologic changes (pregnancy), certain disease states (nephrotic syndrome), and medication effects (oral estrogen therapy). Measuring free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", the unbound fraction of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" in serum, is commonly determined using widely available immunometric assays. These tests are accurate in most clinical settings, including in patients with mild binding protein derangements; however, they can be inaccurate with more significant perturbations (familial dysalbuminemic hyperthyroxinemia). Measuring free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" by equilibrium dialysis is highly accurate, but expensive, not widely available, and rarely necessary."
]
},
{
"type":"p",
"hlId":"6784f7",
"children":[
"Multiple drugs affect thyroid function and replacement ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t35",
"wrapId":"9",
"children":[
"Table 35"
]
}
]
},
")"
]
},
". Patients taking more than 5 to 10 mg/day of biotin, a common over-the-counter supplement, should discontinue it 2 to 5 days before thyroid function testing. Biotin interference causes falsely high free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", and total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" and falsely low TSH, mimicking thyrotoxicosis."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_en_t35"
]
},
{
"type":"p",
"hlId":"7e0731",
"children":[
"Measurement of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" in the setting of hypothyroidism is not necessary; normal levels are maintained unless hypothyroidism is severe. TSH increases first in hypothyroidism, followed by T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" decreases."
]
},
{
"type":"p",
"hlId":"dbff84",
"children":[
"Measurement of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" in hyperthyroidism is recommended in three settings: (1) the evaluation of thyrotoxicosis to identify isolated T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" toxicosis, (2) the assessment of hyperthyroidism severity and therapeutic response, and (3) the differentiation of hyperthyroidism from destructive thyroiditis. In T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" toxicosis, the T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
"-to-T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" ratio is often greater than 20 because of preferential secretion of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
"."
]
},
{
"type":"p",
"hlId":"29512b",
"children":[
"Reverse T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" measurement is not recommended."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"67976a",
"children":[
"Serum thyroid-stimulating hormone is the most sensitive test of thyroid function and is sufficient as an initial test unless central hypothyroidism is suspected."
]
},
{
"type":"keypoint",
"hlId":"f948e3",
"hvc":true,
"children":[
"Triiodothyronine measurement in the setting of hypothyroidism is not necessary or recommended; normal levels are maintained unless hypothyroidism is severe."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5",
"title":{
"__html":"Disorders of Thyroid Function"
},
"titleNode":{
"type":"section-title",
"hlId":"10053d",
"children":[
"Disorders of Thyroid Function"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s4_5_1",
"title":{
"__html":"Thyroid Hormone Excess (Hyperthyroidism and Thyrotoxicosis)"
},
"titleNode":{
"type":"section-title",
"hlId":"bfc800",
"children":[
"Thyroid Hormone Excess (Hyperthyroidism and Thyrotoxicosis)"
]
},
"children":[
{
"type":"p",
"hlId":"c9249c",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Thyrotoxicosis"
]
},
" describes high levels of circulating thyroid hormones (T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
") from any cause. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Hyperthyroidism"
]
},
" is thyrotoxicosis caused by excessive endogenous thyroid hormone production. The prevalence of hyperthyroidism in the United States is 1.3%. In primary hyperthyroidism, the thyroid is the anatomic site of dysfunction. Increased secretion of TSH is a rare secondary cause of hyperthyroidism."
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_1",
"title":{
"__html":"Clinical Features and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"14634f",
"children":[
"Clinical Features and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"8ab212",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t36",
"wrapId":"10",
"children":[
"Table 36"
]
}
]
},
" lists signs and symptoms of thyroid hormone excess. In older adult patients, thyrotoxicosis may be apathetic and present with nonclassical symptoms and signs. Lid lag (eyelid retraction) can be seen in thyrotoxicosis of any cause resulting from increased adrenergic tone. The presence of a diffuse goiter and recently developed proptosis is sufficient for a diagnosis of Graves disease. Thyrotoxicosis is diagnosed with a low TSH and elevated free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and/or total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
". Thyroid scintigraphy with RAIU can verify the cause. RAIU is high (>30%) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f14",
"wrapId":"10",
"children":[
"Figure 14"
]
}
]
},
")"
]
},
" or inappropriately normal in hyperthyroidism and low (<10%) in other causes of thyrotoxicosis, such as destructive thyroiditis or exogenous thyroid hormone ingestion ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f15",
"wrapId":"10",
"children":[
"Figure 15"
]
}
]
},
")"
]
},
". Thyroid-stimulating immunoglobulin (TSI) or thyrotropin (TSH) receptor antibodies (TRAb) measurement can identify Graves disease with high sensitivity and specificity. Third-generation TRAb measurement may provide a quicker and more cost efficient diagnosis than RAIU."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_en_t36",
"mk19_b_en_f14",
"mk19_b_en_f15"
]
},
{
"type":"p",
"hlId":"33ed13",
"children":[
"Additional testing may be indicated when the clinical diagnosis is unclear; when RAIU is unavailable or unreliable because of exposure to iodine (amiodarone, iodinated contrast) or lithium; or when scintigraphy is contraindicated (in pregnancy and lactation). Thyroid ultrasonography can assess for patterns of vascularity."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"606c35",
"children":[
"The diagnosis of thyrotoxicosis is based on biochemical testing demonstrating a low thyroid-stimulating hormone level and elevated concentrations of free thyroxine and/or total triiodothyronine."
]
},
{
"type":"keypoint",
"hlId":"5c323a",
"children":[
"Thyroid scintigraphy with determination of radioactive iodine uptake can verify the cause of thyrotoxicosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_2",
"title":{
"__html":"Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"82887a",
"children":[
"Causes"
]
},
"children":[
{
"type":"p",
"hlId":"df4153",
"children":[
"Causes of thyrotoxicosis are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t37",
"wrapId":"11",
"children":[
"Table 37"
]
}
]
},
". Graves disease, toxic MNG, and toxic adenoma are the most common causes of hyperthyroidism."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_en_t37"
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_2_1",
"title":{
"__html":"Graves Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"2d0cfb",
"children":[
"Graves Disease"
]
},
"children":[
{
"type":"p",
"hlId":"db3cc1",
"children":[
"Graves disease can affect the thyroid, ocular muscles, and skin. In iodine-sufficient geographic areas, this disease causes 80% of the cases of hyperthyroidism. Graves disease is an autoimmune thyroid disorder primarily in women, peaking among patients aged 30 to 60 years. It is more common in patients with other autoimmune disorders or a family history of thyroid autoimmunity. T lymphocytes become sensitized to thyroid antigens and stimulate B lymphocytes to produce TSI or TRAb. The thyroid is diffusely enlarged, may have a bruit, and has a firm, smooth texture on examination; cervical lymphadenopathy may also occur. Systolic hypertension, tachycardia, hyperreflexia, and warm moist skin are often present, although older patients may have an atypical presentation."
]
},
{
"type":"p",
"hlId":"810213",
"children":[
"Graves ophthalmopathy affects 25% of patients. Cigarette smoking is a risk factor. Clinical manifestations include periorbital edema, chemosis (conjunctival edema), proptosis (protrusion of the globe) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f16",
"wrapId":"12",
"children":[
"Figure 16"
]
}
]
},
")"
]
},
", diplopia (due to oculomotor paresis), and vision loss. Graves ophthalmopathy does not respond to the treatment of hyperthyroidism and severe cases may require glucocorticoids, surgery, or teprotumumab, a human monoclonal antibody inhibitor of insulin-like growth factor-1 receptor."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_en_f16"
]
},
{
"type":"p",
"hlId":"829d7b",
"children":[
"Pretibial myxedema ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f17",
"wrapId":"13",
"children":[
"Figure 17"
]
}
]
},
")"
]
},
" is a rare infiltrative dermopathy of Graves disease affecting 2% to 3% of patients."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_en_f17"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2219af",
"children":[
"In Graves disease, the thyroid is diffusely enlarged, may have a bruit, and has a firm, smooth texture on examination; cervical lymphadenopathy may also occur."
]
},
{
"type":"keypoint",
"hlId":"223524",
"children":[
"Moderate to severe Graves ophthalmopathy may require treatment with glucocorticoids, surgery, or teprotumumab."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_2_2",
"title":{
"__html":"Toxic Adenoma and Multinodular Goiter"
},
"titleNode":{
"type":"section-title",
"hlId":"e3e800",
"children":[
"Toxic Adenoma and Multinodular Goiter"
]
},
"children":[
{
"type":"p",
"hlId":"784428",
"children":[
"Toxic adenoma and MNG typically affect older adults. Thyroid nodules produce thyroid hormones independent of TSH stimulation. Exposure to iodine (iodinated contrast in CT scanning or cardiac catheterization, amiodarone) may change a nontoxic adenoma to a toxic adenoma."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_2_3",
"title":{
"__html":"Destructive Thyroiditis"
},
"titleNode":{
"type":"section-title",
"hlId":"263bf0",
"children":[
"Destructive Thyroiditis"
]
},
"children":[
{
"type":"p",
"hlId":"925e3d",
"children":[
"Destructive thyroiditis releases, in unregulated fashion, preformed thyroid hormone from inflamed, damaged thyroid follicles. Causes are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t38",
"wrapId":"14",
"children":[
"Table 38"
]
}
]
},
". Thyroiditis typically has three phases: thyrotoxic, hypothyroid, and return to euthyroidism. The first two phases can last up to 3 months each. A person has increased risk of additional bouts of thyroiditis after the initial thyroiditis has resolved."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_en_t38"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"befcf5",
"children":[
"Most patients with thyrotoxicosis benefit from β-blockers to reduce adrenergic symptoms rapidly. Atenolol and metoprolol are preferred because of once-daily dosing and their cardioselective nature. High-dose propranolol has the added benefit of decreasing the peripheral conversion of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" to T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", but it is noncardioselective and requires two or three times daily dosing."
]
},
{
"type":"p",
"hlId":"c0dd39",
"children":[
"The three treatment modalities for the underlying cause of hyperthyroidism are (1) thionamides (methimazole and propylthiouracil [PTU]), (2) ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I ablative therapy, and (3) thyroidectomy. The choice of treatment depends on the cause of hyperthyroidism and patient preference; endocrinology referral is recommended. For patients undergoing ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy or thyroidectomy who are 65 years and older or who have cardiac disease or multiple comorbidities, short-term methimazole use is recommended to normalize thyroid function before treatment."
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_3_1",
"title":{
"__html":"Graves Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"2d0cfb",
"children":[
"Graves Disease"
]
},
"children":[
{
"type":"p",
"hlId":"cf2819",
"children":[
"Thionamides are often used in the initial treatment of Graves hyperthyroidism. Up to 50% of patients have spontaneous remission of hyperthyroidism within 24 months; remission is more common in patients with small goiters requiring only low doses. Recurrent hyperthyroidism is likely if TRAb levels remain elevated when the drug is discontinued. If Graves hyperthyroidism recurs, definitive treatment with ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy or thyroidectomy is recommended."
]
},
{
"type":"p",
"hlId":"bb2b49",
"children":[
"Methimazole is the thionamide of choice because PTU has been associated with fatal hepatic necrosis. PTU is preferred during the first trimester of pregnancy because of the potential teratogenic effects of methimazole. Agranulocytosis and liver dysfunction are rare but serious adverse effects of thionamides. Before treatment, baseline complete blood count with a differential and liver profile should be assessed because Graves disease itself may cause similar abnormalities. In the setting of fever or pharyngitis, agranulocytosis should be suspected and the patient's neutrophil count urgently assessed. Liver function should be assessed in any patient with symptoms or signs of hepatic dysfunction (jaundice, icterus)."
]
},
{
"type":"p",
"hlId":"681e38",
"children":[
"The goal of ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I ablative therapy in Graves disease is to cause hypothyroidism. Women receiving ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy must avoid pregnancy for 6 to 12 months after treatment. In patients with Graves ophthalmopathy, the acute escalation of thyroid autoantibody titers following ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy may exacerbate ocular symptoms. Pretreatment of Graves ophthalmopathy or selection of alternative treatments depends on severity of ophthalmopathy."
]
},
{
"type":"p",
"hlId":"435e5c",
"children":[
"Thyroidectomy in Graves hyperthyroidism is most appropriate for patients with a large goiter that causes compressive symptoms, moderate to severe Graves ophthalmopathy, or coexistent thyroid cancer or primary hyperparathyroidism."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_3_2",
"title":{
"__html":"Other Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"b8b649",
"children":[
"Other Causes"
]
},
"children":[
{
"type":"p",
"hlId":"4de19f",
"children":[
"First-line therapy for a toxic adenoma or toxic MNG is either ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy or thyroid surgery. The choice is determined by patient preference, presence of compressive symptoms, and access to a high-volume thyroid surgeon."
]
},
{
"type":"p",
"hlId":"e8a8f9",
"children":[
"Destructive thyroiditis is managed with β-blockers to control adrenergic symptoms and NSAIDs or high-dose glucocorticoid therapy for pain control in painful thyroiditis. Because of the transient nature of thyroiditis, thionamides, ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy, and thyroid surgery have no role in treatment."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"13bacd",
"children":[
"Most patients with thyrotoxicosis benefit from β-blockers to reduce adrenergic symptoms."
]
},
{
"type":"keypoint",
"hlId":"fe0e92",
"children":[
"Three treatment modalities for hyperthyroidism are (1) thionamides (methimazole and propylthiouracil), (2) radioactive iodine ablative therapy, and (3) thyroidectomy; the choice of treatment depends on the cause of the hyperthyroidism and patient preference."
]
},
{
"type":"keypoint",
"hlId":"db0e30",
"children":[
"In Graves disease, antithyroid drugs (thionamides) are associated with up to a 50% spontaneous remission rate within 24 months; remission is more common in patients with small goiters."
]
},
{
"type":"keypoint",
"hlId":"457d56",
"children":[
"Agranulocytosis and liver dysfunction are rare but serious adverse effects of thionamides."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_1_4",
"title":{
"__html":"Subclinical Hyperthyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"a64972",
"children":[
"Subclinical Hyperthyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"02e89d",
"children":[
"Subclinical hyperthyroidism is diagnosed by TSH suppression with normal T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" levels. This disease affects 0.7% of the U.S. population. Approximately 0.5% to 7% progress to overt hyperthyroidism per year and 5% to 12% revert to normal thyroid function. The most common cause is toxic MNG."
]
},
{
"type":"p",
"hlId":"0a09f5",
"children":[
"Subclinical hyperthyroidism increases the risk of atrial fibrillation, and cardiovascular events. There are higher rates of hip fracture with subclinical hyperthyroidism. Whether treatment of subclinical hyperthyroidism reduces fracture risk is unknown."
]
},
{
"type":"p",
"hlId":"83784f",
"children":[
"TSH normalizes after 6 weeks in more than 25% of patients with subclinical hyperthyroidism. Therefore, observation and rechecking thyroid function before treatment is reasonable unless the risk of complications, such as cardiac disease, is high. The risk of cardiovascular and skeletal complications is higher with TSH levels less than 0.1 μU/mL (0.1 mU/L). Treatment is recommended for TSH less than 0.1 μU/mL (0.1 mU/L), cardiac risk factors, heart disease, osteoporosis, or high risk for osteoporosis, regardless of symptoms. Treatment is generally recommended in all patients with symptoms."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5da6fd",
"children":[
"Subclinical hyperthyroidism is diagnosed based on persistent suppression of thyroid-stimulating hormone but normal thyroxine and triiodothyronine levels."
]
},
{
"type":"keypoint",
"hlId":"c0b2e9",
"children":[
"Treatment of subclinical hyperthyroidism is recommended for patients with thyroid-stimulating hormone level less than 0.1 μU/mL (0.1 mU/L) and cardiac risk factors, heart disease, high risk for osteoporosis, or symptoms."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2",
"title":{
"__html":"Thyroid Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"e4f722",
"children":[
"Thyroid Hormone Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"6f8712",
"children":[
"Thyroid hormone deficiency affects more than 10 million Americans. It is 10 times more common in women than men."
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2_1",
"title":{
"__html":"Clinical Features and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"14634f",
"children":[
"Clinical Features and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"148e90",
"children":[
"Signs and symptoms of thyroid hormone deficiency are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t36",
"wrapId":"15",
"children":[
"Table 36"
]
}
]
},
". Thyroid hormone deficiency is associated with anemia, elevated LDL cholesterol, and hyponatremia."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_b_en_t36"
]
},
{
"type":"p",
"hlId":"e9aff5",
"children":[
"The diagnosis of primary hypothyroidism is made by measuring TSH, and, if elevated, measuring free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". TSH is elevated in both overt and subclinical hypothyroidism, but free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" is low in overt hypothyroidism and normal in subclinical hypothyroidism. Thyroid peroxidase (TPO) antibodies are present in most patients with Hashimoto thyroiditis, but measurement is unnecessary unless the diagnosis is unclear."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1de9b2",
"children":[
"The diagnosis of hypothyroidism is made by measuring thyroid-stimulating hormone, and, if elevated, then measuring free thyroxine."
]
},
{
"type":"keypoint",
"hlId":"1a3bc5",
"children":[
"Thyroid-stimulating hormone is elevated in overt and subclinical hypothyroidism, but free thyroxine is low in overt hypothyroidism and normal in subclinical hypothyroidism."
]
},
{
"type":"keypoint",
"hlId":"53d893",
"hvc":true,
"children":[
"Thyroid peroxidase antibodies are present in most patients with Hashimoto thyroiditis, but measurement is unnecessary unless the diagnosis is unclear."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2_2",
"title":{
"__html":"Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"82887a",
"children":[
"Causes"
]
},
"children":[
{
"type":"p",
"hlId":"5e8ff8",
"children":[
"Causes of thyroid hormone deficiency are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t39",
"wrapId":"16",
"children":[
"Table 39"
]
}
]
},
". The most common cause in the United States is autoimmune thyroid failure; iodine deficiency is the most common cause globally. Iodine deficiency is uncommon in the United States because of food fortification (iodized salt). Central hypothyroidism is also uncommon."
]
},
{
"type":"inline-wrap",
"wrapId":"16",
"contentIds":[
"mk19_b_en_t39"
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2_2_1",
"title":{
"__html":"Primary Hypothyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"a5e1a1",
"children":[
"Primary Hypothyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"768d99",
"children":[
"Hashimoto thyroiditis (chronic lymphocytic thyroiditis) is an autoimmune thyroid disorder characterized by diffuse infiltration of the thyroid by lymphocytes and plasma cells with subsequent follicular atrophy and scarring. It is more common in patients with other autoimmune disorders (e.g., type 1 diabetes mellitus) or a family history of thyroid autoimmunity. Diffuse goiter is more common in younger patients. Most patients (90%) have TPO antibodies. The risk of developing hypothyroidism is fourfold higher in euthyroid patients with TPO antibodies."
]
},
{
"type":"p",
"hlId":"e054f9",
"children":[
"Hypothyroidism occurs in all patients after thyroidectomy and 20% of patients after thyroid lobectomy. Postablative hypothyroidism occurs after ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy within 1 year in 90% of patients with Graves disease and in 60% of patients with toxic MNG, but may be delayed for many years."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8562e9",
"children":[
"The most common cause of primary hypothyroidism in the United States is autoimmune thyroid failure secondary to Hashimoto thyroiditis (chronic lymphocytic thyroiditis)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2_2_2",
"title":{
"__html":"Subclinical Hypothyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"fd1af6",
"children":[
"Subclinical Hypothyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"fdbc47",
"children":[
"Subclinical hypothyroidism is common (5%-10%), typically asymptomatic, and diagnosed by a high TSH and a normal free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". Repeating the measurement in 6 to 8 weeks confirms persistent TSH elevation. Of patients with subclinical hypothyroidism, 2% to 4% per year progress to overt hypothyroidism, whereas thyroid function will spontaneously revert to normal in one third of patients. The normal range for TSH increases with age, and a TSH level of up to 7.9 μU/mL (7.9 mU/L) is within the normal range for persons 80 years and older."
]
},
{
"type":"p",
"hlId":"538362",
"children":[
"Subclinical hypothyroidism with TSH greater than 10 μU/mL (10 mU/L) may be a risk factor for coronary artery disease and heart failure. No evidence indicates that treating subclinical hypothyroidism improves quality of life, cognitive function, blood pressure, or weight, but in patients with elevated LDL cholesterol, normalization of the TSH will lower LDL."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_2_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"31e34c",
"children":[
"Levothyroxine is the recommended treatment for thyroid hormone deficiency. Treatment goals include normalizing TSH (in primary hypothyroidism) or free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" (in central hypothyroidism) and resolving signs and symptoms of hypothyroidism. Beginning a full replacement dose (1.6 μg/kg lean body weight) is appropriate for most patients with overt hypothyroidism. Lower initial doses (25-50 μg/day) are recommended in older adults and patients with cardiac disease. Repeating TSH at least 6 weeks after dose initiation or modification allows assessment of treatment adequacy."
]
},
{
"type":"p",
"hlId":"f76942",
"children":[
"T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
"-containing compounds are not recommended because of their short half-life, resulting in nonphysiologic T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" spikes. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" alone or in combination with T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", including desiccated thyroid, has no clear benefit in treatment of hypothyroidism."
]
},
{
"type":"p",
"hlId":"2aa3c5",
"children":[
"Treatment of subclinical hypothyroidism with a TSH greater than 20 μU/mL (20 mU/L) should be initiated with levothyroxine at 25 to 50 μg/day. Treating patients with TSH values 5 to 20 μU/mL (5-20 mU/L) results in unclear benefits and potential harm. A recent study showed no benefit to treatment of subclinical hypothyroidism in patients older than 65 years with TSH levels between 4.6 and 20 μU/mL (4.6-20 mU/L), although outcomes were assessed at 2 years, potentially before cardiovascular benefits could emerge. Overtreatment is seen in more than one third of patients older than 65 years, increasing the risk for dysrhythmia and osteoporosis. Treatment for subclinical hypothyroidism with TSH less than 20 μU/mL (20 mU/L) should be considered in younger patients, those attempting to become pregnant, or if significant symptoms are present."
]
},
{
"type":"p",
"hlId":"145551",
"children":[
"Oral levothyroxine is absorbed in the jejunum and ileum. Ideally, it is taken on an empty stomach (60 minutes before breakfast or coffee). If adherence to morning administration is difficult, levothyroxine can be taken before bed. Missed doses can be taken the following day in younger patients. The absorption of an orally administered dose is 70% to 80% under optimum fasting conditions. Gastrointestinal disorders (such as celiac disease) may impact absorption and result in higher-than-expected levothyroxine dose requirements. Medications can also interfere with the absorption or metabolism of levothyroxine (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t35",
"wrapId":"17",
"children":[
"Table 35"
]
}
]
},
")"
]
},
". For levothyroxine therapy, nonadherence with dosing, different bioavailability of the generic options, TSH assay interference from heterophile antibodies and biotin-containing agents, decreased T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" to T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" conversion, incorrect drug storage, increased drug metabolism, and an increased drug requirement because of weight gain or pregnancy are other possible causes of treatment-refractory hypothyroidism."
]
},
{
"type":"inline-wrap",
"wrapId":"17",
"contentIds":[
"mk19_b_en_t35"
]
},
{
"type":"p",
"hlId":"064ae2",
"children":[
"The symptoms of Hashimoto thyroiditis, including fatigue, increased need for sleep, arthralgia, myalgia, and dry mouth and eyes, may not resolve completely with adequate levothyroxine therapy. Patients with severe symptoms and thyroid autoimmunity may improve with thyroidectomy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"51b56a",
"children":[
"Levothyroxine is the treatment of choice for thyroid hormone deficiency; it should be taken on an empty stomach 60 minutes before consuming breakfast or coffee."
]
},
{
"type":"keypoint",
"hlId":"ced095",
"children":[
"Triiodothyronine-containing compounds are not recommended to treat hypothyroidism because of their short half-life, which causes spikes in triiodothyronine levels."
]
},
{
"type":"keypoint",
"hlId":"8a66ba",
"hvc":true,
"children":[
"Overtreatment of subclinical hypothyroidism is common, especially in patients older than 65 years; treatment for subclinical hypothyroidism with thyroid-stimulating hormone less than 20 μU/mL (20 mU/L) should be considered only in younger patients, those attempting to become pregnant, or if significant symptoms are present."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_5_3",
"title":{
"__html":"Drug-Induced Thyroid Dysfunction"
},
"titleNode":{
"type":"section-title",
"hlId":"7b4a50",
"children":[
"Drug-Induced Thyroid Dysfunction"
]
},
"children":[
{
"type":"p",
"hlId":"c797c2",
"children":[
"Many medications can affect thyroid function (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t35",
"wrapId":"18",
"children":[
"Table 35"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"18",
"contentIds":[
"mk19_b_en_t35"
]
},
{
"type":"p",
"hlId":"b5756b",
"children":[
"Amiodarone has a high iodine content and prolonged half-life of 60 days. Amiodarone causes transient TSH increases in all patients, with normalization after a few months. One of four patients taking amiodarone develop thyroid dysfunction, and one of five develop hypothyroidism (most often with pre-existing Hashimoto thyroiditis). Of those taking amiodarone, 5% develop thyrotoxicosis, either type 1 in those with pre-existing Graves disease or toxic nodules (Jod-Basedow phenomenon) or type 2 (destructive thyroiditis). This distinction is important because the former is treated with thionamides and the latter with glucocorticoids. Thyroid ultrasound with Doppler studies helps distinguish these types by showing increased vascularity with type 1 and decreased vascularity with type 2. Amiodarone discontinuation depends on the patient's cardiac condition and thyrotoxicosis type."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3a8b6c",
"children":[
"Thyroid dysfunction occurs in approximately 25% of patients taking amiodarone, most commonly hypothyroidism."
]
},
{
"type":"keypoint",
"hlId":"962251",
"children":[
"Amiodarone causes transient thyroid-stimulating hormone increases in all patients, with normalization after a few months."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_6",
"title":{
"__html":"Thyroid Function and Dysfunction in Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"630c1f",
"children":[
"Thyroid Function and Dysfunction in Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"318524",
"children":[
"Thyroid hormones are essential for normal fetal development. The size of the maternal thyroid increases up to 40% during pregnancy and production of T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" increases up to 50% to compensate for the increased TBG associated with pregnancy. Iodine requirements also increase up to 50%. The American Thyroid Association recommends counseling pregnant and lactating women to take a daily oral supplement containing 150 μg of iodine, which is included in some but not all prenatal vitamins. Universal TSH screening in pregnant women is not recommended. Patients who should be screened because of an increased risk of thyroid dysfunction are those 30 years and older and those with known hypothyroidism or a strong family history of thyroid dysfunction; previous head and neck irradiation; previous neck surgery; positive TPO, TSI, or TRAb status; or other autoimmune disorders."
]
},
{
"type":"p",
"hlId":"8afd15",
"children":[
"Changes in thyroid function tests are depicted in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f18",
"wrapId":"19",
"children":[
"Figure 18"
]
}
]
},
". Placental human chorionic gonadotropin stimulates thyroid hormone secretion, and TSH may decrease as a result. In the late first trimester (weeks 7-12), the lower limit of the TSH reference range decreases by 0.4 μU/mL (0.4 mU/L) and the upper limit by 0.5 μU/mL (0.5 mU/L). TSH gradually returns to the nonpregnant reference range in the second and third trimester."
]
},
{
"type":"inline-wrap",
"wrapId":"19",
"contentIds":[
"mk19_b_en_f18"
]
},
{
"type":"p",
"hlId":"f6d9a0",
"children":[
"Total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" concentrations increase linearly during pregnancy. After week 16, the upper limit of the total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" reference range can be estimated by multiplying the nonpregnant upper limit by 1.5. Free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" measured by indirect analogue immunoassays are inaccurate in pregnancy unless method- and trimester-specific reference ranges are applied."
]
},
{
"type":"p",
"hlId":"df7138",
"children":[
"Endocrinology consultation is indicated for thyrotoxicosis management during pregnancy. Gestational thyrotoxicosis from high human chorionic gonadotropin levels is the most common cause of transient TSH suppression. If serum total or free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" remains within the trimester-specific reference range, treatment is unnecessary. Women with moderate to severe hyperthyroidism in early pregnancy should be treated with PTU because it is less teratogenic than methimazole. After the first trimester, women can be transitioned to methimazole. Thyroid function during treatment with thionamides should be followed closely, keeping the serum total or free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" at or just above the trimester-specific reference range to avoid fetal hypothyroidism."
]
},
{
"type":"p",
"hlId":"4282e8",
"children":[
"Graves disease affects 0.2% of pregnant women and is diagnosed by classic physical findings or elevated TSI or TRAb. Women with Graves disease have high-risk pregnancies and should be followed by maternal-fetal specialists throughout the pregnancy."
]
},
{
"type":"p",
"hlId":"f40a0e",
"children":[
"Hypothyroidism in pregnancy increases the risk of miscarriage, premature birth, and low birth weight; additionally, it is associated with decreased infant neurocognitive function. Levothyroxine is the recommended treatment."
]
},
{
"type":"p",
"hlId":"c75be8",
"children":[
"For women with preexisting hypothyroidism, levothyroxine dosing can be empirically increased by 30% when pregnancy is confirmed. In treatment-naïve pregnant women with positive TPO antibodies, levothyroxine is started if the TSH level is 2.5 μU/mL (2.5 mU/L) or higher. Treatment is indicated for pregnant women who are TPO-negative if their TSH is above the pregnancy-specific reference range. TSH should be measured every 4 weeks for the first half of pregnancy and around 30 weeks in all hypothyroid women and in those at risk for hypothyroidism (antibody positive or history of hemithyroidectomy or ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy). A TSH level less than 2.5 μU/mL (2.5 mU/L) should be targeted in treated women with hypothyroidism before conception and during pregnancy."
]
},
{
"type":"p",
"hlId":"83d914",
"children":[
"Thyroid nodules detected in pregnant women are evaluated as in nonpregnant patients. The timing of FNAB, whether during or after pregnancy, is determined by the cancer risk and patient preference. Endocrinology consultation is indicated for management of thyroid cancer detected during pregnancy. Pregnant women with a history of thyroid cancer should be managed as when they were not pregnant."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5d6787",
"children":[
"Hypothyroidism in pregnancy increases the risk of miscarriage, premature birth, and low birth weight; additionally, it is associated with decreased infant neurocognitive function."
]
},
{
"type":"keypoint",
"hlId":"70af6e",
"children":[
"For women with preexisting hypothyroidism, levothyroxine dosing can be empirically increased by 30% when pregnancy is confirmed."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_7",
"title":{
"__html":"Nonthyroidal Illness Syndrome (Euthyroid Sick Syndrome)"
},
"titleNode":{
"type":"section-title",
"hlId":"51b5a9",
"children":[
"Nonthyroidal Illness Syndrome (Euthyroid Sick Syndrome)"
]
},
"children":[
{
"type":"p",
"hlId":"09abe5",
"children":[
"Nonthyroidal illness syndrome (NTIS) commonly occurs in patients who are hospitalized and critically ill. Up to 75% of hospitalized patients have physiologic thyroid function test abnormalities. Nonthyroidal illness suppresses thyrotropin-releasing hormone, resulting in suppressed but detectable TSH. An undetectable TSH is not consistent with NTIS. Infrequently, TSH can be mildly elevated in recovery from NTIS, but a TSH level of 20 μU/mL (20 mU/L) or greater is not consistent with NTIS. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" is typically normal, but because of decreased deiodinase activity, T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" decreases and reverse T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" increases (biologically inactive). TBG decreases in illness, lowering total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" levels. NTIS may be an adaptive response to systemic illness and macronutrient restriction."
]
},
{
"type":"p",
"hlId":"f82298",
"children":[
"Treatment of NTIS is not recommended because of unclear clinical benefit. In general, thyroid function should not be assessed in hospitalized patients unless there is a strong clinical suspicion of thyroid dysfunction. If NTIS is diagnosed, TSH should be rechecked approximately 6 weeks after the patient has recovered from nonthyroidal illness to assess for normalization."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f6bf01",
"hvc":true,
"children":[
"Treatment of nonthyroidal illness syndrome is not recommended because of a lack of significant clinical benefit."
]
},
{
"type":"keypoint",
"hlId":"c928c4",
"hvc":true,
"children":[
"Thyroid function should not be assessed in hospitalized patients unless there is a strong clinical suspicion of thyroid dysfunction."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_8",
"title":{
"__html":"Thyroid Emergencies"
},
"titleNode":{
"type":"section-title",
"hlId":"580149",
"children":[
"Thyroid Emergencies"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s4_8_1",
"title":{
"__html":"Thyroid Storm"
},
"titleNode":{
"type":"section-title",
"hlId":"a4bdee",
"children":[
"Thyroid Storm"
]
},
"children":[
{
"type":"p",
"hlId":"2d537e",
"children":[
"Thyroid storm is a rare serious disorder (up to 30% mortality) characterized by severe thyrotoxicosis and life-threatening complications. Serum thyroid hormone concentrations do not differentiate thyroid storm from severe thyrotoxicosis."
]
},
{
"type":"p",
"hlId":"2d8496",
"children":[
"Presentation often follows discontinuation of antithyroid drug therapy, systemic illness, labor and delivery, surgery, exposure to radioiodinated contrast media, or trauma. Patients with Graves disease are at higher risk. Clinical manifestations include high fever, tachycardia, altered mental status, and cardiac and hepatic dysfunction. A scoring system ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t40",
"wrapId":"20",
"children":[
"Table 40"
]
}
]
},
")"
]
},
" can suggest the diagnosis, but is limited by poor specificity; thyroid storm is diagnosed clinically."
]
},
{
"type":"inline-wrap",
"wrapId":"20",
"contentIds":[
"mk19_b_en_t40"
]
},
{
"type":"p",
"hlId":"c22c9e",
"children":[
"Management includes ICU-level care, treatment of any precipitant illness, thyrotoxicosis-directed therapy, and supportive measures. Thyrotoxicosis is treated with intravenous β-blockers, thionamide for hyperthyroidism (typically PTU, transitioning to methimazole when stable), intravenous high-dose glucocorticoids, and potassium iodide. Iodide should be administered at least 1 hour after thionamides to avoid increasing substrate to the gland. Glucocorticoid therapy is a potent inhibitor of peripheral T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" to T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" conversion. Bile acid sequestrants can be used to decrease T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" levels, especially in patients unable to take thionamides. Plasmapheresis or emergent thyroidectomy is used for patients responding poorly to medical therapy. Definitive treatment with thyroidectomy or ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"131"
]
},
"I therapy is indicated in patients who survive thyroid storm."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"438e55",
"children":[
"Thyroid storm is a rare disorder with high mortality (up to 30%) characterized by severe thyrotoxicosis and life-threating complications."
]
},
{
"type":"keypoint",
"hlId":"a6733f",
"children":[
"Thyroid storm often occurs with discontinuation of antithyroid drug therapy, systemic illness, labor and delivery, surgery, exposure to radioiodinated contrast media, or trauma."
]
},
{
"type":"keypoint",
"hlId":"8638bb",
"children":[
"ICU-level care; treating any precipitating illness; and intravenous β-blockers, thionamide, intravenous high-dose glucocorticoids, and potassium iodide are all used to manage thyroid storm."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_8_2",
"title":{
"__html":"Myxedema Coma"
},
"titleNode":{
"type":"section-title",
"hlId":"10eb0f",
"children":[
"Myxedema Coma"
]
},
"children":[
{
"type":"p",
"hlId":"c5f217",
"children":[
"Myxedema coma is a rare but life-threatening presentation of severe hypothyroidism with hemodynamic compromise. Mortality is high (up to 40%), and ICU-level care is required. Risk factors for myxedema coma are female sex, advanced age, cold exposure, or a precipitant event (myocardial infarction, sepsis, trauma, anesthesia, or stroke) in patients with untreated hypothyroidism. Mental status changes ranging from lethargy to coma to psychosis, coupled with hypothermia, are the most common manifestations. Bradycardia, hypotension, or decreased respiration rate with hypoxia and hypercapnia is frequently present. TSH is typically elevated; however, without an overtly low free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", myxedema coma is unlikely even in the presence of marked TSH elevation. Hyponatremia and hypoglycemia may be present. Cortisol measurement should be included in the initial testing to assess for concomitant cortisol deficiency."
]
},
{
"type":"p",
"hlId":"b63c8b",
"children":[
"Aggressive supportive measures include fluids, vasopressors if necessary, ventilator support, and passive rather than active warming to avoid vasodilation and worsened hypotension. Glucocorticoids (100 mg intravenous hydrocortisone every 8 hours) are administered empirically before thyroid hormone is initiated to treat possible concomitant adrenal insufficiency. If a random cortisol level is greater than 18 μg/dL (497 nmol/L), hydrocortisone can be discontinued. Thyroid hormone replacement requires consideration of the need to normalize thyroid hormone levels rapidly and the risk of a fatal cardiac event caused by thyroid hormone administration. Initial treatment is 200 to 400 μg intravenous levothyroxine, followed by a daily oral dose of 1.6 μg/kg. Intravenous daily dosing should be reduced to 75% of the oral dose. Lower levothyroxine doses are recommended with advanced age or cardiac disease. Concomitant treatment with T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" may also be considered. Treatment goals are improved mental status, metabolic parameters, and cardiopulmonary function. When the patient stabilizes, transition to oral levothyroxine is the goal."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8f96d0",
"children":[
"Myxedema coma is a life-threatening presentation of severe hypothyroidism with hemodynamic compromise; it most often occurs when a systemic illness is superimposed on previously undiagnosed or untreated hypothyroidism."
]
},
{
"type":"keypoint",
"hlId":"0c94f1",
"children":[
"Treatment of myxedema coma includes aggressive supportive measures; glucocorticoids are administered empirically before thyroid hormone is initiated to treat possible concomitant adrenal insufficiency."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s4_9",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315-389. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28056690",
"target":"_blank"
},
"children":[
"PMID: 28056690"
]
},
" doi:10.1089/thy.2016.0457"
]
},
{
"type":"reference",
"children":[
"Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31088853",
"target":"_blank"
},
"children":[
"PMID: 31088853"
]
},
" doi:10.1136/bmj.l2006"
]
},
{
"type":"reference",
"children":[
"Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018;378:2411-2419. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29924956",
"target":"_blank"
},
"children":[
"PMID: 29924956"
]
},
" doi:10.1056/NEJMcp1709318"
]
},
{
"type":"reference",
"children":[
"Burch HB. Drug effects on the thyroid. N Engl J Med. 2019;381:749-761. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31433922",
"target":"_blank"
},
"children":[
"PMID: 31433922"
]
},
" doi:10.1056/NEJMra1901214"
]
},
{
"type":"reference",
"children":[
"Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017;40:1289-1301. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28695483",
"target":"_blank"
},
"children":[
"PMID: 28695483"
]
},
" doi:10.1007/s40618-017-0706-y"
]
},
{
"type":"reference",
"children":[
"Guldvog I, Reitsma LC, Johnsen L, et al. Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: a randomized trial. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M18-0284",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:453-464. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30856652",
"target":"_blank"
},
"children":[
"PMID: 30856652"
]
}
]
},
{
"type":"reference",
"children":[
"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26462967",
"target":"_blank"
},
"children":[
"PMID: 26462967"
]
},
" doi:10.1089/thy.2015.0020"
]
},
{
"type":"reference",
"children":[
"Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-1421. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27521067",
"target":"_blank"
},
"children":[
"PMID: 27521067"
]
}
]
},
{
"type":"reference",
"children":[
"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748-1761. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28467880",
"target":"_blank"
},
"children":[
"PMID: 28467880"
]
},
" doi:10.1056/NEJMoa1614949"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t33":{
"id":"mk19_b_en_t33",
"number":33,
"bookId":"en",
"title":{
"__html":"Summary of 2015 American Thyroid Association Guidelines: Sonographic Patterns and Recommendations for Fine-Needle Aspiration Biopsy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"99cdb8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 33. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t33"
}
]
},
"Summary of 2015 American Thyroid Association Guidelines: Sonographic Patterns and Recommendations for Fine-Needle Aspiration Biopsy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de4062",
"class":"col hd l",
"children":[
"Sonographic Pattern"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52ac74",
"class":"col hd l",
"children":[
"Representative Image"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5a7ad",
"class":"col hd l",
"children":[
"Description"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe24dc",
"class":"col hd l",
"children":[
"Estimated Risk of Malignancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4b3da",
"class":"col hd l",
"children":[
"Size Threshold for Fine-Needle Aspiration Biopsy"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0bfd5",
"class":"cell txt l",
"children":[
"Benign"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e6be0",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f31",
"children":[
"Figure 31"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a7e49",
"class":"cell txt l",
"children":[
"Pure cyst (anechoic with no internal blood flow)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acc03e",
"class":"cell txt l",
"children":[
"<1%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cab672",
"class":"cell txt l",
"children":[
"Fine-needle aspiration biopsy not recommended"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73b6a4",
"class":"cell txt l",
"children":[
"Very low suspicion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe0226",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f32",
"children":[
"Figure 32"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eee4e5",
"class":"cell txt l",
"children":[
"Some mixed cystic and solid nodules (spongiform nodules)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dcfa03",
"class":"cell txt l",
"children":[
"<3%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1eb31",
"class":"cell txt l",
"children":[
"2 cm",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe09ec",
"class":"cell txt l",
"children":[
"Low suspicion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e12ecb",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f33",
"children":[
"Figure 33"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c446d9",
"class":"cell txt l",
"children":[
"Isoechoic/hyperechoic solid nodules; some mixed cystic and solid nodules"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89fcdf",
"class":"cell txt l",
"children":[
"5%-10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"722937",
"class":"cell txt l",
"children":[
"1.5 cm"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60348c",
"class":"cell txt l",
"children":[
"Intermediate suspicion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86d1af",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f34",
"children":[
"Figure 34"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"152a23",
"class":"cell txt l",
"children":[
"Hypoechoic solid nodules"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71f57b",
"class":"cell txt l",
"children":[
"10%-20%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e796a",
"class":"cell txt l",
"children":[
"1 cm"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4481a8",
"class":"cell txt l",
"children":[
"High suspicion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e3b7c",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f35",
"children":[
"Figure 35"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ebe11",
"class":"cell txt l",
"children":[
"Hypoechoic solid nodules with one or more suspicious feature",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c36bd3",
"class":"cell txt l",
"children":[
">70%-90%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e796a",
"class":"cell txt l",
"children":[
"1 cm"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Microcystic spaces occupying more than 50% of the nodule volume is highly correlated with benign cytology."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Clinical observation is an acceptable alternative."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Microcalcifications, shape taller than wide in the transverse plane, irregular margins, extrathyroidal extension or pathologic lymph nodes (image shows hypoechoic solid nodule with irregular margins)."
],
[
"Adapted with permission from Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26462967",
"target":"_blank"
},
"children":[
"PMID: 26462967"
]
},
" doi:10.1089/thy.2015.0020 Copyright 2016, Mary Ann Liebert, Inc."
]
]
},
"mk19_b_en_t34":{
"id":"mk19_b_en_t34",
"number":34,
"bookId":"en",
"title":{
"__html":"Diagnoses Obtained by Fine-Needle Aspiration Biopsy of Thyroid Nodules and Risk for Malignancy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"67caf1",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 34. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t34"
}
]
},
"Diagnoses Obtained by Fine-Needle Aspiration Biopsy of Thyroid Nodules and Risk for Malignancy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49be75",
"class":"col hd l",
"children":[
"FNAB Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b4991",
"class":"col hd l",
"children":[
"Risk for Malignancy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe4dbc",
"class":"col hd l",
"children":[
"Management"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0bfd5",
"class":"cell txt l",
"children":[
"Benign"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a00813",
"class":"cell txt l",
"children":[
"0%-3%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67df69",
"class":"cell txt l",
"children":[
"Repeat ultrasound in 6-24 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"237d59",
"class":"cell txt l",
"children":[
"Atypia of uncertain significance/follicular lesion of uncertain significance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ff3ea",
"class":"cell txt l",
"children":[
"10%-30%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed6975",
"class":"cell txt l",
"children":[
"Repeat FNAB in 3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46b4dc",
"class":"cell txt l",
"children":[
"Suspicious for follicular neoplasm"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e968e3",
"class":"cell txt l",
"children":[
"25%-40%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37a361",
"class":"cell txt l",
"children":[
"Lobectomy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7397c7",
"class":"cell txt l",
"children":[
"Suspicious for malignancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33891c",
"class":"cell txt l",
"children":[
"50%-75%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e2f48",
"class":"cell txt l",
"children":[
"Lobectomy or total thyroidectomy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72dbe7",
"class":"cell txt l",
"children":[
"Malignant"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a06ee4",
"class":"cell txt l",
"children":[
"97%-99%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e2f48",
"class":"cell txt l",
"children":[
"Lobectomy or total thyroidectomy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48668a",
"class":"cell txt l",
"children":[
"Nondiagnostic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89fcdf",
"class":"cell txt l",
"children":[
"5%-10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe7097",
"class":"cell txt l",
"children":[
"Repeat FNAB"
]
},
" ",
{
"type":"p",
"hlId":"ba54c3",
"class":"cell txt l",
"children":[
"If two nondiagnostic FNABs, treat with surgery"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"FNAB = fine-needle aspiration biopsy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Risk for malignancy by cytology diagnosis includes noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), a “pre-cancerous” lesion. If counted as benign, the risk of malignancy is reduced for all Bethesda categories except nondiagnostic and benign readings. Data from Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27:1341-1346. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29091573",
"target":"_blank"
},
"children":[
"PMID: 29091573"
]
},
" doi:10.1089/thy.2017.0500"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"If American Thyroid Association “high suspicion” pattern, repeat ultrasound and FNAB in 6 to 12 months."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Supplementary management strategies include molecular genetic testing of the nodule and selective use of thyroid scintigraphy (when serum thyroid-stimulation hormone level is low-normal)."
]
]
},
"mk19_b_en_t35":{
"id":"mk19_b_en_t35",
"number":35,
"bookId":"en",
"title":{
"__html":"Medications that Affect Thyroid Function, Measurement, or Replacement"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"25fd0c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 35. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t35"
}
]
},
"Medications that Affect Thyroid Function, Measurement, or Replacement"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cdc4b",
"class":"col hd l",
"children":[
"Mechanism of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"626c25",
"class":"col hd l",
"children":[
"Drugs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a40097",
"class":"cell txt l",
"children":[
"Decreased absorption or enterohepatic circulation of levothyroxine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9640c",
"class":"cell txt l",
"children":[
"Calcium"
]
},
" ",
{
"type":"p",
"hlId":"502a85",
"class":"cell txt l",
"children":[
"Proton pump inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"cefa8a",
"class":"cell txt l",
"children":[
"Iron"
]
},
" ",
{
"type":"p",
"hlId":"dc4e1a",
"class":"cell txt l",
"children":[
"Cholestyramine"
]
},
" ",
{
"type":"p",
"hlId":"7bb583",
"class":"cell txt l",
"children":[
"Aluminum hydroxide"
]
},
" ",
{
"type":"p",
"hlId":"5daa0e",
"class":"cell txt l",
"children":[
"Raloxifene"
]
},
" ",
{
"type":"p",
"hlId":"38ec5e",
"class":"cell txt l",
"children":[
"Soybean oil"
]
},
" ",
{
"type":"p",
"hlId":"27d85b",
"class":"cell txt l",
"children":[
"Sucralfate"
]
},
" ",
{
"type":"p",
"hlId":"775903",
"class":"cell txt l",
"children":[
"Psyllium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a922b9",
"class":"cell txt l",
"children":[
"Recommend that levothyroxine administration be separated from these medications by several hours"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a48514",
"class":"cell txt l",
"children":[
"Increased metabolism of levothyroxine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"221fb3",
"class":"cell txt l",
"children":[
"Phenytoin"
]
},
" ",
{
"type":"p",
"hlId":"051b8d",
"class":"cell txt l",
"children":[
"Carbamazepine"
]
},
" ",
{
"type":"p",
"hlId":"335c29",
"class":"cell txt l",
"children":[
"Rifampin"
]
},
" ",
{
"type":"p",
"hlId":"4f0812",
"class":"cell txt l",
"children":[
"Phenobarbital"
]
},
" ",
{
"type":"p",
"hlId":"a4b119",
"class":"cell txt l",
"children":[
"Sertraline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"318112",
"class":"cell txt l",
"children":[
"Higher levothyroxine doses may be required to maintain TSH in the normal range"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a199e",
"class":"cell txt l",
"children":[
"Thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3453ee",
"class":"cell txt l",
"children":[
"May cause hypo- or hyperthyroidism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0a569",
"class":"cell txt l",
"children":[
"Lithium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7ee4a",
"class":"cell txt l",
"children":[
"Interferon alfa"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e5365",
"class":"cell txt l",
"children":[
"Interleukin-2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a9e74",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4b167",
"class":"cell txt l",
"children":[
"Sunitinib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1de5a",
"class":"cell txt l",
"children":[
"Immune checkpoint inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8cc501",
"class":"cell txt l",
"children":[
"Nivolumab, pembrolizumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5fd11",
"class":"cell txt l",
"children":[
"De novo development of antithyroid antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7ee4a",
"class":"cell txt l",
"children":[
"Interferon alfa"
]
},
" ",
{
"type":"p",
"hlId":"a1de5a",
"class":"cell txt l",
"children":[
"Immune checkpoint inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"fda758",
"class":"cell txt l",
"children":[
"Alemtuzumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02d807",
"class":"cell txt l",
"children":[
"May develop Hashimoto thyroiditis, Graves disease, or painless thyroiditis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0abfc6",
"class":"cell txt l",
"children":[
"Inhibition of TSH synthesis or release"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"d7e7bc",
"class":"cell txt l",
"children":[
"Dopamine"
]
},
" ",
{
"type":"p",
"hlId":"3a4960",
"class":"cell txt l",
"children":[
"Metformin"
]
},
" ",
{
"type":"p",
"hlId":"311eb6",
"class":"cell txt l",
"children":[
"Dobutamine"
]
},
" ",
{
"type":"p",
"hlId":"dd13ef",
"class":"cell txt l",
"children":[
"Octreotide"
]
},
" ",
{
"type":"p",
"hlId":"f2040f",
"class":"cell txt l",
"children":[
"Bexarotene"
]
},
" ",
{
"type":"p",
"hlId":"89dd3f",
"class":"cell txt l",
"children":[
"Mitotane"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2b7b0",
"class":"cell txt l",
"children":[
"Leads to TSH suppression; TSH should be rechecked 6-8 weeks after these medications are stopped to assess for return to normal."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1de5a",
"class":"cell txt l",
"children":[
"Immune checkpoint inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8eff7",
"class":"cell txt l",
"children":[
"Ipilimumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f352b",
"class":"cell txt l",
"children":[
"Increased thyroxine-binding globulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9ece1",
"class":"cell txt l",
"children":[
"Estrogen"
]
},
" ",
{
"type":"p",
"hlId":"cc465c",
"class":"cell txt l",
"children":[
"Tamoxifen"
]
},
" ",
{
"type":"p",
"hlId":"4cf38f",
"class":"cell txt l",
"children":[
"Methadone"
]
},
" ",
{
"type":"p",
"hlId":"89dd3f",
"class":"cell txt l",
"children":[
"Mitotane"
]
},
" ",
{
"type":"p",
"hlId":"493bb4",
"class":"cell txt l",
"children":[
"Fluorouracil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"722dca",
"class":"cell txt l",
"children":[
"False elevation of total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" levels; free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" are a more accurate reflection of hormone levels"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c28f34",
"class":"cell txt l",
"children":[
"Decreased thyroxine-binding globulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18c149",
"class":"cell txt l",
"children":[
"Androgen therapy"
]
},
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"8f855e",
"class":"cell txt l",
"children":[
"Niacin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e63dd",
"class":"cell txt l",
"children":[
"False lowering of total T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" levels; free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" and T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" are a more accurate reflection of hormone levels"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f0a7f",
"class":"cell txt l",
"children":[
"Decreased thyroid hormone synthesis, release or activation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27f128",
"class":"cell txt l",
"children":[
"Iodine (iodinated contrast dye, topical povidone–iodine, kelp)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3c3ee",
"class":"cell txt l",
"children":[
"Wolff-Chaikoff effect decreasing iodine uptake, thyroid hormone synthesis and release, decreased T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" to T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" conversion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"764abc",
"class":"cell txt l",
"children":[
"Escape from Wolff-Chaikoff effect may lead to thyrotoxicosis due to Jod-Basedow effect"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0a569",
"class":"cell txt l",
"children":[
"Lithium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7268e7",
"class":"cell txt l",
"children":[
"Spurious lab results"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" ",
{
"type":"p",
"hlId":"66a653",
"class":"cell txt l",
"children":[
"Biotin"
]
},
" ",
{
"type":"p",
"hlId":"932961",
"class":"cell txt l",
"children":[
"Carbamazepine, oxcarbazepine, phenytoin"
]
},
" ",
{
"type":"p",
"hlId":"eabf8f",
"class":"cell txt l",
"children":[
"Enoxaparin, heparin"
]
},
" ",
{
"type":"p",
"hlId":"af6a2b",
"class":"cell txt l",
"children":[
"Salsalate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"149fb2",
"class":"cell txt l",
"children":[
"High free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", low T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", normal TSH"
]
},
" ",
{
"type":"p",
"hlId":"128d6d",
"class":"cell txt l",
"children":[
"High free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", low TSH"
]
},
" ",
{
"type":"p",
"hlId":"438036",
"class":"cell txt l",
"children":[
"Low free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", low T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", normal TSH"
]
},
" ",
{
"type":"p",
"hlId":"b1b119",
"class":"cell txt l",
"children":[
"High free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", high T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", normal TSH"
]
},
" ",
{
"type":"p",
"hlId":"438036",
"class":"cell txt l",
"children":[
"Low free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", low T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
", normal TSH"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" = triiodothyronine; T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" = thyroxine; TSH = thyroid-stimulating hormone."
]
]
},
"mk19_b_en_t36":{
"id":"mk19_b_en_t36",
"number":36,
"bookId":"en",
"title":{
"__html":"Clinical Manifestations of Thyrotoxicosis and Thyroid Hormone Deficiency<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"bbeb2f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 36. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t36"
}
]
},
"Clinical Manifestations of Thyrotoxicosis and Thyroid Hormone Deficiency",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e306ab",
"class":"col hd l",
"children":[
"Sign or Symptom"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d6a7a",
"class":"col hd l",
"children":[
"Thyrotoxicosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4f722",
"class":"col hd l",
"children":[
"Thyroid Hormone Deficiency"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0db377",
"class":"cell txt l",
"children":[
"General"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78aa35",
"class":"cell txt l",
"children":[
"Fatigue, weight loss,",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" heat intolerance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb3e95",
"class":"cell txt l",
"children":[
"Fatigue, weight gain, cold intolerance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0df19",
"class":"cell txt l",
"children":[
"Neuropsychiatric"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e20ed2",
"class":"cell txt l",
"children":[
"Decreased concentration, anxiety, irritability, insomnia"
]
},
" ",
{
"type":"p",
"hlId":"ea90f6",
"class":"cell txt l",
"children":[
"Hyperreflexia, tremor, lid lag"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34a9fe",
"class":"cell txt l",
"children":[
"Decreased concentration, depression, psychomotor retardation, hypersomnolence"
]
},
" ",
{
"type":"p",
"hlId":"c4117a",
"class":"cell txt l",
"children":[
"Delayed relaxation of deep tendon reflexes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"59ea4b",
"class":"cell txt l",
"children":[
"Cardiovascular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2cbb05",
"class":"cell txt l",
"children":[
"Palpitations, tachycardia, systolic hypertension, high-output heart failure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c356a",
"class":"cell txt l",
"children":[
"Bradycardia, diastolic hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"08029b",
"class":"cell txt l",
"children":[
"Hyperphagia, increased frequency of bowel movements, loose stools, diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5249f2",
"class":"cell txt l",
"children":[
"Constipation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3005cd",
"class":"cell txt l",
"children":[
"Genitourinary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e59179",
"class":"cell txt l",
"children":[
"Menstrual disturbance (oligomenorrhea, amenorrhea)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c6d46",
"class":"cell txt l",
"children":[
"Menstrual disturbance (menorrhagia)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b3d4d",
"class":"cell txt l",
"children":[
"Musculoskeletal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d1993",
"class":"cell txt l",
"children":[
"Muscle weakness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"99e0ad",
"class":"cell txt l",
"children":[
"Myalgia, arthralgia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e490c2",
"class":"cell txt l",
"children":[
"Cutaneous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a166f",
"class":"cell txt l",
"children":[
"Hair loss, increased sweating, increased oil production/acne, periorbital edema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e10386",
"class":"cell txt l",
"children":[
"Hair loss, dry skin, brittle nails, periorbital edema, lateral truncation of the eyebrows, myxedematous skin changes"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Goiter may be present in thyrotoxicosis or thyroid hormone deficiency. See text for physical findings characteristic of Graves disease."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Mild weight gain can occur with subclinical hyperthyroidism (thyroid-stimulating hormone suppression without T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" or T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" elevation) due to appetite stimulation."
]
]
},
"mk19_b_en_t37":{
"id":"mk19_b_en_t37",
"number":37,
"bookId":"en",
"title":{
"__html":"Causes of Thyrotoxicosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a416fd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 37. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t37"
}
]
},
"Causes of Thyrotoxicosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"589189",
"class":"col hd l",
"children":[
"Disorder"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e503b",
"class":"cell txt l",
"children":[
"Graves disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e51ee",
"class":"cell txt l",
"children":[
"Common; TRAb-mediated activation of TSHR"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35b675",
"class":"cell txt l",
"children":[
"Toxic multinodular goiter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"645d25",
"class":"cell txt l",
"children":[
"Common; autonomously functioning thyroid tissue"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"384b76",
"class":"cell txt l",
"children":[
"Toxic adenoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"645d25",
"class":"cell txt l",
"children":[
"Common; autonomously functioning thyroid tissue"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a199e",
"class":"cell txt l",
"children":[
"Thyroiditis"
]
},
" ",
{
"type":"p",
"hlId":"e3f241",
"class":"cell txt l",
"children":[
"(acute, subacute, painless)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e29929",
"class":"cell txt l",
"children":[
"Common; thyroid inflammation resulting in release of stored thyroid hormones"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abe373",
"class":"cell txt l",
"children":[
"Medication induced"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a64ea7",
"class":"cell txt l",
"children":[
"Common; amiodarone, lithium, interferon alfa, interleukin-2, tyrosine kinase inhibitors, immune checkpoint inhibitors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cae6a2",
"class":"cell txt l",
"children":[
"Thyrotoxicosis factitia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c9926",
"class":"cell txt l",
"children":[
"Common; administration of exogenous thyroid hormone; ingestion of pork or beef products contaminated with thyroid tissue"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e0333",
"class":"cell txt l",
"children":[
"HCG-mediated"
]
},
" ",
{
"type":"p",
"hlId":"246fb6",
"class":"cell txt l",
"children":[
"(pregnancy, trophoblastic disease, germ cell tumor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8cf7f",
"class":"cell txt l",
"children":[
"Common in pregnancy, other forms rare; indiscriminant binding of HCG to TSHR due to common alpha subunit shared by TSH and HCG"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d815f5",
"class":"cell txt l",
"children":[
"Struma ovarii"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"299612",
"class":"cell txt l",
"children":[
"Rare; autonomously functioning thyroid tissue in an ovarian teratoma accounting for >50% of the tumor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e59388",
"class":"cell txt l",
"children":[
"Follicular thyroid cancer metastases"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eef1e0",
"class":"cell txt l",
"children":[
"Rare; autonomously functioning follicular thyroid carcinoma metastases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f1c1f",
"class":"cell txt l",
"children":[
"Thyrotrope adenoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"69c5c5",
"class":"cell txt l",
"children":[
"Rare; TSH-secreting pituitary adenoma"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HCG = human chorionic gonadotropin; TRAb = thyrotropin (TSH) receptor antibodies; TSH = thyroid-stimulating hormone; TSHR = TSH receptor."
]
]
},
"mk19_b_en_t38":{
"id":"mk19_b_en_t38",
"number":38,
"bookId":"en",
"title":{
"__html":"Causes of Destructive Thyroiditis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7e7e23",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 38. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t38"
}
]
},
"Causes of Destructive Thyroiditis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"589189",
"class":"col hd l",
"children":[
"Disorder"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e34af8",
"class":"cell txt l",
"children":[
"Painless (silent) thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02762a",
"class":"cell txt l",
"children":[
"Seen with underlying autoimmune thyroid disease (Hashimoto thyroiditis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d51f90",
"class":"cell txt l",
"children":[
"Postpartum thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c1819",
"class":"cell txt l",
"children":[
"Painless thyroiditis occurring postpartum; permanent hypothyroidism occurs in 20% of cases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c89ac8",
"class":"cell txt l",
"children":[
"Medication-induced thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b126e",
"class":"cell txt l",
"children":[
"Painless thyroiditis; amiodarone, lithium, interferon alfa, interleukin-2, tyrosine kinase inhibitors, immune checkpoint inhibitors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc4b6b",
"class":"cell txt l",
"children":[
"Subacute thyroiditis (de Quervain or subacute granulomatous)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9452dd",
"class":"cell txt l",
"children":[
"Painful thyroiditis; follows a viral upper respiratory tract infection; associated with elevated erythrocyte sedimentation rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2448",
"class":"cell txt l",
"children":[
"Infectious (suppurative)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a4765",
"class":"cell txt l",
"children":[
"Painful thyroiditis; ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Streptococcus"
]
},
" species infection usually seen in immunocompromised patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aae99d",
"class":"cell txt l",
"children":[
"Radiation-induced thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58403d",
"class":"cell txt l",
"children":[
"Painful thyroiditis; occurs after radioactive iodine therapy or neck external beam radiation therapy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_en_t39":{
"id":"mk19_b_en_t39",
"number":39,
"bookId":"en",
"title":{
"__html":"Causes of Thyroid Hormone Deficiency"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"32d502",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 39. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t39"
}
]
},
"Causes of Thyroid Hormone Deficiency"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"589189",
"class":"col hd l",
"children":[
"Disorder"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7f11f",
"class":"cell txt l",
"children":[
"Hashimoto thyroiditis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33fcb5",
"class":"cell txt l",
"children":[
"Autoimmune thyroid disorder associated with anti-TPO antibodies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5043ab",
"class":"cell txt l",
"children":[
"Post-thyroidectomy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26999a",
"class":"cell txt l",
"children":[
"Treatment of Graves disease, goiter, thyroid nodules, or thyroid cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73bce0",
"class":"cell txt l",
"children":[
"Post-radioactive iodine therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b538f4",
"class":"cell txt l",
"children":[
"Treatment of Graves disease or toxic adenoma/multinodular goiter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14f737",
"class":"cell txt l",
"children":[
"External beam radiation to the neck"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a37f44",
"class":"cell txt l",
"children":[
"Treatment of Hodgkin lymphoma and head/neck malignancies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a199e",
"class":"cell txt l",
"children":[
"Thyroiditis"
]
},
" ",
{
"type":"p",
"hlId":"759e3d",
"class":"cell txt l",
"children":[
"(acute, subacute, suppurative)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a9242",
"class":"cell txt l",
"children":[
"Typically a transient hypothyroidism prior to recovery of euthyroid state"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"401d1d",
"class":"cell txt l",
"children":[
"Central hypothyroidism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a2fa7",
"class":"cell txt l",
"children":[
"TSH deficiency from hypothalamic or pituitary disease; TSH should not be used to assess for replacement dose adequacy; T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" level should be used for dosing"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f58f40",
"class":"cell txt l",
"children":[
"Congenital hypothyroidism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fd3b",
"class":"cell txt l",
"children":[
"Universal neonatal screening in the United States (incidence is 1 in 3500)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e2a31",
"class":"cell txt l",
"children":[
"Iodide deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5392c3",
"class":"cell txt l",
"children":[
"Common worldwide in developing countries with severe iodine deficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"297c95",
"class":"cell txt l",
"children":[
"Drug-induced"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bb8c7",
"class":"cell txt l",
"children":[
"Amiodarone, lithium, interferon alfa, interleukin-2, iodine, thionamides (methimazole), ethionamide, tyrosine kinase inhibitors (sunitinib), immune checkpoint inhibitors (ipilimumab)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Anti-TPO = anti-thyroid peroxidase; TSH = thyroid-stimulating hormone; T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" = thyroxine."
]
]
},
"mk19_b_en_t40":{
"id":"mk19_b_en_t40",
"number":40,
"bookId":"en",
"title":{
"__html":"Diagnostic Criteria for Thyroid Storm<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ac0bf6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 40. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t40"
}
]
},
"Diagnostic Criteria for Thyroid Storm",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"e42614",
"class":"col hd l",
"children":[
"Thermoregulatory Dysfunction"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a438b",
"class":"cell txt l",
"children":[
"Temp"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57ee61",
"class":"cell txt li",
"children":[
"99-99.9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a301e7",
"class":"cell txt li",
"children":[
"100-100.9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0f1f5",
"class":"cell txt li",
"children":[
"101-101.9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bf31c",
"class":"cell txt l",
"children":[
"15"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"360255",
"class":"cell txt li",
"children":[
"102-102.9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98f137",
"class":"cell txt l",
"children":[
"20"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fda0ee",
"class":"cell txt li",
"children":[
"103-103.9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e296a",
"class":"cell txt l",
"children":[
"25"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e84bd",
"class":"cell txt li",
"children":[
"≥104.0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34173c",
"class":"cell txt l",
"children":[
"30"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c8eaa",
"class":"col hd l",
"children":[
"Central Nervous System Effects"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e384f0",
"class":"cell txt l",
"children":[
"Absent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f038f4",
"class":"cell txt li",
"children":[
"Agitation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98f137",
"class":"cell txt l",
"children":[
"20"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e555ca",
"class":"cell txt li",
"children":[
"Delirium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c3fc0",
"class":"cell txt li",
"children":[
"Psychosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fac00",
"class":"cell txt li",
"children":[
"Extreme lethargy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34173c",
"class":"cell txt l",
"children":[
"30"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"82d09d",
"class":"cell txt li",
"children":[
"Seizure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e05a8",
"class":"cell txt li",
"children":[
"Coma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"056006",
"class":"col hd l",
"children":[
"Gastrointestinal-Hepatic Dysfunction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e384f0",
"class":"cell txt l",
"children":[
"Absent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b9937",
"class":"cell txt li",
"children":[
"Diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7bca5",
"class":"cell txt li",
"children":[
"Nausea/vomiting"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb7523",
"class":"cell txt li",
"children":[
"Abdominal pain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98f137",
"class":"cell txt l",
"children":[
"20"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77e4d1",
"class":"cell txt li",
"children":[
"Unexplained jaundice"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"88d1dc",
"class":"col hd l",
"children":[
"Cardiovascular Dysfunction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db3d58",
"class":"cell txt l",
"children":[
"Tachycardia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e19a2",
"class":"cell txt li",
"children":[
"90-109"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3eda5",
"class":"cell txt li",
"children":[
"110-119"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ec656",
"class":"cell txt li",
"children":[
"120-129"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bf31c",
"class":"cell txt l",
"children":[
"15"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44c1de",
"class":"cell txt li",
"children":[
"130-139"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98f137",
"class":"cell txt l",
"children":[
"20"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e0353",
"class":"cell txt li",
"children":[
"≥140"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e296a",
"class":"cell txt l",
"children":[
"25"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"198fa1",
"class":"cell txt l",
"children":[
"Congestive heart failure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e384f0",
"class":"cell txt li",
"children":[
"Absent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt li",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0d24f",
"class":"cell txt lii",
"children":[
"Pedal edema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt li",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88a070",
"class":"cell txt lii",
"children":[
"Bibasilar rales"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt li",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bf31c",
"class":"cell txt l",
"children":[
"15"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4057c",
"class":"cell txt lii",
"children":[
"Pulmonary edema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e384f0",
"class":"cell txt li",
"children":[
"Absent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd058d",
"class":"cell txt li",
"children":[
"Present"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"756233",
"class":"col hd l",
"children":[
"Precipitant History"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"328929",
"class":"cell txt l",
"children":[
"Positive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"In patients with severe thyrotoxicosis, points are assigned to the highest weighted description acceptable in each category and scores totaled. When it is not possible to distinguish the effects of an intercurrent illness from those of the severe thyrotoxicosis per se, points are awarded such as to favor the diagnosis of storm and hence, empiric therapy. A score of 45 or greater is highly suggestive of thyroid storm, a score of 25 to 44 is suggestive of impending storm, and a score below 25 is unlikely to represent thyroid storm."
],
[
"Reproduced with permission from Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263-77. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/8325286",
"target":"_blank"
},
"children":[
"PMID: 8325286"
]
},
" doi.org/10.1016/S0889-8529(18)30165-8 ©1993 Elsevier, Inc."
]
]
}
}
}